CDC HUMAN INFLUENZA VIRUS REAL-TIME RT-PCR DIAGNOSTIC PANEL, INFLUENZA A/B TYPING KIT

K133869 · Center For Disease Control and Prevention (Cdc) · OZE · Jan 17, 2014 · Microbiology

Device Facts

• Record ID: K133869
• Device Name: CDC HUMAN INFLUENZA VIRUS REAL-TIME RT-PCR DIAGNOSTIC PANEL, INFLUENZA A/B TYPING KIT
• Applicant: Center For Disease Control and Prevention (Cdc)
• Product Code: OZE · Microbiology
• Decision Date: Jan 17, 2014
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 866.3980
• Device Class: Class 2

Indications for Use

The Influenza A/B Typing Kit contains reagents and controls of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel and is intended for use in real-time RT-PCR (rRT-PCR) assays on an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR instrument in conjunction with clinical and epidemiological information: - For qualitative detection of influenza virus type A or B from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs [NPS], nasal swabs [NS], throat swabs [TS], nasal aspirates [NA], nasal washes [NW] and dual nasopharyngeal/throat swabs [NPS/TS]), and lower respiratory tract specimens (including bronchoalveolar lavage [BAL], bronchial wash [BW], tracheal aspirate [TA], sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture: - To provide epidemiologic information for surveillance of circulating influenza viruses. Performance characteristics for influenza were established during a season when seasonal influenza viruses A/H1 and A/H3 were the predominant influenza A viruses in circulation and during a season when the A/H1 odm09 influenza virus was the predominant influenza A virus in circulation. Performance characteristics may vary with other emerging influenza A viruses. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted unless a BSL 3+ facility is available to receive and culture specimens. All users, analysts, and any person reporting results from use of this device should be trained to perform and interpret the results from this procedure by a competent instructor prior to use. CDC Influenza Division will limit the distribution of this device to only those users who have successfully completed a training course provided by CDC instructors or designees.

Device Story

In vitro diagnostic kit; utilizes real-time RT-PCR technology to detect influenza A and B viral RNA. Input: respiratory specimens (swabs, aspirates, washes, sputum, tissue) or viral culture. Process: nucleic acid extraction followed by rRT-PCR amplification on Applied Biosystems 7500 Fast Dx instrument. Output: qualitative detection of influenza A and B. Used in clinical laboratory settings by trained personnel. Results interpreted alongside clinical/epidemiological data to support diagnosis and surveillance. Modification allows ordering specific panel components to manage reagent supply and minimize waste.

Clinical Evidence

No new clinical data provided. The device relies on the performance characteristics established for the predicate CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (K132508), which were validated during seasonal influenza circulation (A/H1, A/H3, and A/H1pdm09).

Technological Characteristics

Real-time RT-PCR assay; utilizes ABI 7500 Fast Dx instrument with SDS software v1.4. Compatible with multiple nucleic acid extraction kits (QIAamp Viral RNA, MagNA Pure series, NucliSENS easyMAG). Enzyme master mixes: Invitrogen SuperScript III Platinum or Quanta BioSciences qScript. Standardized rRT-PCR workflow.

Indications for Use

Indicated for qualitative detection of influenza A and B viral RNA in upper and lower respiratory tract specimens from patients with signs/symptoms of respiratory infection or viral culture. Used for epidemiologic surveillance. Requires trained personnel; distribution limited to CDC-trained users.

Regulatory Classification

Identification

A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses:(1) Influenza A and Influenza B; (2) Influenza A subtype H1 and Influenza A subtype H3; (3) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B; (4) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus; and (7) Adenovirus.

Special Controls

*Classification.* Class II (special controls). The special controls are:(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;” (2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and (3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.

Predicate Devices

• CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel (K132508)

Submission Summary (Full Text)

{0}

SPECIAL 510(k): Device Modification
OIR Review Memorandum (Decision Making Document is Attached)

To: Centers for Disease Control and Prevention
RE: K133869

This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable:

1. The name and 510(k) number of the SUBMITTER'S previously cleared device:

CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel

510(k) number: K132508

2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).

3. Description of the device MODIFICATION(S):

The modification presented in this special 510(k) consisted of a revised package insert for the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/B typing kit. Recently, additional assays have been included in the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel and cleared by FDA to accommodate the new influenza virus subtypes. The consumption of the various assays within the panel may be different since the prevalence of influenza virus types and subtypes vary from season to season. To address the consequent variation in consumption, CDC plans to provide the users with an option to order different configurations of specific components of the panel (including the Influenza A/B typing in this special 510(k)) so that their supply of reagents can be managed efficiently minimizing the waste. The different components of CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel will be accompanied by revised labeling (package inserts) and the current submission is to clear the first component, i.e., Influenza A/B typing.

4. The FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

5. Comparison Information

Similarities

| | Predicate Device | Modified Device |
| --- | --- | --- |
| | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (K132508) | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit (K133869) |
| Intended Use | The CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel is intended for use in real- time RT-PCR (rRT-PCR) assays on | The Influenza A/B Typing Kit contains reagents and controls of the CDC Human Influenza Virus Real-Time RT- |

{1}

Page 2 of 5

| an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR Instrument in conjunction with clinical and epidemiological information:
- For qualitative detection of influenza virus type A or B from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs [NPS], nasal swabs [NS], throat swabs [TS], nasal aspirates [NA], nasal washes [NW] and dual nasopharyngeal/throat swabs [NPS/TS]), and lower respiratory tract specimens (including bronchoalveolar lavage [BAL], bronchial wash [BW], tracheal aspirate [TA], sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture;
- For determination of the subtype of seasonal human influenza A viruses as seasonal A/H1, A/H3, and/or A/H1pdm09 from viral RNA in upper respiratory tract clinical specimens (including NPS, NS, TS, NA, NW and NPS/TS) and lower respiratory tract specimens (including BAL, BW, TA, sputum and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture;
- For the determination of the genetic lineage of human influenza B viruses as B/Victoria or B/Yamagata lineage from viral RNA in upper respiratory tract clinical specimens (including NPS, NS, TS, NA, NW, and NPS/TS) from human patients with signs and symptoms of respiratory infection and/or from viral culture;
- For the presumptive identification of virus in patients who may be infected with influenza A subtype A/H5 (Asian lineage) from viral RNA in human respiratory specimens and viral culture in conjunction with clinical and epidemiological risk factors;
- To provide epidemiological information for surveillance of | PCR Diagnostic Panel and is intended for use in Real-time RT-PCR assays on an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR Instrument in conjunction with clinical and epidemiological information:
- For qualitative detection of influenza virus type A or B from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs, nasal swabs, throat swabs, nasal aspirates, nasal washes and dual nasopharyngeal/throat swabs), and lower respiratory tract specimens (including bronchoalveolar lavages, bronchial washes, tracheal aspirates, sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture;
- To provide epidemiologic information for surveillance of the circulating influenza viruses Performance characteristics for influenza were established during a season when seasonal influenza viruses A/H1 and A/H3 were the predominant influenza A viruses in circulation and during a season when the A/H1pdm09 influenza virus was the predominant influenza A virus in circulation. Performance characteristics may vary with other emerging influenza A viruses.
Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or |
| --- | --- |

{2}

Page 3 of 5

| | circulating influenza viruses. Performance characteristics for influenza were established during a season when seasonal influenza viruses A/H1 and A/H3 were the predominant influenza A viruses in circulation and during a season when the A/H1pdm09 influenza virus was the predominant influenza A virus in circulation. Performance characteristics may vary with other emerging influenza A viruses. Testing with the influenza H5a and H5b primer and probe sets should not be performed unless the patient meets the most current U.S. Department of Health and Human Services (DHHS) clinical and epidemiological criteria for testing suspect A/H5 specimens. The definitive identification of influenza A/H5 (Asian lineage) either directly from patient specimens or from virus cultures requires additional laboratory testing, along with clinical and epidemiological assessment in consultation with national influenza surveillance experts. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted unless a BSL 3+ facility is available to receive and culture specimens. | local health department for testing. Viral culture should not be attempted unless a BSL 3+ facility is available to receive and culture specimens. |
| --- | --- | --- |
| Specimen Types | Nasopharyngeal swabs, nasal swabs, throat swabs, nasal aspirates, nasal washes and dual nasopharyngeal/throat swabs, bronchoalveolar lavages, bronchial aspirates, bronchial washes, tracheal aspirates, sputum, and lung tissue and virus culture. Only upper respiratory specimens for influenza B genetic lineage determination | Nasopharyngeal swabs, nasal swabs, throat swabs, nasal aspirates, nasal washes and dual nasopharyngeal/throat swabs, bronchoalveolar lavages, bronchial aspirates, bronchial washes, tracheal aspirates, sputum, and lung tissue and virus culture. |
| Technology | Real-time RT-PCR | Same |
| Required | Applied Biosystems 7500 Fast Dx Real- | Same |

{3}

Page 4 of 5

| Instrumentation | Time PCR
Instrument with SDS software version 1.4 | |
| --- | --- | --- |
| Nucleic Acid Extraction | Yes | Same |
| Extraction Method | • QIAamp® Viral RNA Mini Kit, Qiagen Inc.
• MagNA Pure Compact -Total Nucleic Acid Kit, Roche Applied Science
• MagNA Pure Compact – RNA Isolation Kit, Roche Applied Science
• MagNA Pure LC - RNA Isolation Kit II, Roche Applied Science
• Qiagen QIAcube with QIAamp® Viral RNA Mini Kit, Qiagen Inc.
• NucliSENS® easyMAG®, bioMerieux | Same |
| Enzyme Master Mix | Invitrogen SuperScript™ III Platinum® One-Step Quantitative RT-PCR Kits (with or without ROX)
OR
Quanta BioSciences qScript™ One-Step qRT-PCR Kit, Low ROX | Same |

## Differences

The package insert has been updated to include only Influenza A/B typing kit, one of the components of FDA cleared CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel.

| | Predicate Device | Modified Device |
| --- | --- | --- |
| | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel (K132508) | CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit (K133869) |
| Organism Detected | Universal influenza A viruses (animal and human), Swine-origin influenza A viruses, Influenza B viruses, Influenza A subtypes: seasonal A/H1, A/H3, A/H1pdm09, and A/H5, Influenza B/Yamagata and B/Victoria lineages | Universal influenza A viruses (animal and human), Influenza B viruses |

## 6. Design Control Activities Summary:

A "Declaration of Conformity" statement was submitted for the verification activities, and manufacturing facility. The statement was signed by the Deputy Brach Chief, Division of Scientific Resources, CDC and Acting Brach Chief of the Virus Surveillance and Diagnostic Branch, CDC. It indicates that:

{4}

Page 5 of 5

## Verification Activities

To the best of my knowledge, the verification activities, as required by the risk analysis for the modification, were performed by the designated individual(s) and the results demonstrate that the predetermined acceptance criteria were met.

## Manufacturing Facility

The CDC Division of Scientific Resources manufacturing facility is in conformance with the design control requirements as specified in 21 CFR 820.30 and the records are available for review.

In conclusion, the modified labeling is truthful and accurate. The changes do not affect the performance of the test and it is therefore substantially equivalent to the current cleared test.

## 7. Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared device.